We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $519M
1-Year Est. Return 339.42%
This Fund
S&P 500
This Quarter Est. Return
-1.57%
1 Year Est. Return
+339.42%
3 Year Est. Return
+563.8%
5 Year Est. Return
+1,003.88%
10 Year Est. Return
–
AUM
$211M
AUM Growth
-$14.6M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
–
Closed
–

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKRO
1
DELISTED
Akero Therapeutics
AKRO
$90M 42.68%
3,954,858
– –
TPTX
2
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$50.4M 23.91%
1,340,265
– –
DTIL icon
3
Precision BioSciences
DTIL
$215M
$35.8M 16.98%
142,171
– –
APLS
4
DELISTED
Apellis Pharmaceuticals
APLS
$24.1M 11.43%
1,000,000
– –
YARW
5
Yarrow Bioscience
YARW
$98.8M
$6.55M 3.11%
406
– –
VRNA
6
DELISTED
Verona Pharma
VRNA
$4M 1.9%
875,000
– –

Similar funds

CFA
Churchill Financial Advisors Louisville, Kentucky $519M AUM
CFG
Compton Financial Group Towson, Maryland $519M AUM 14.76% 1-Year Est. Return
MWM
Mindset Wealth Management Indianapolis, Indiana $519M AUM 46.03% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $520M AUM 21.73% 1-Year Est. Return
WS
Wendel SE Paris $519M AUM 48.2% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
MWC
MBM Wealth Consultants Chesterfield, Missouri $519M AUM 16.88% 1-Year Est. Return
PDIP
Palo Duro Investment Partners Chicago, Illinois $518M AUM 22.62% 1-Year Est. Return

venBio Partners's Q3 2019 Portfolio in Review

As of Q3 2019, venBio Partners held 6 positions worth $211M, down 6.5% from $225M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q3 2019: portfolio turnover was 0%. venBio Partners opened no new positions and made no exits, leaving the 6-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • venBio Partners's ten largest holdings make up 100% of its $211M portfolio in Q3 2019.
  • venBio Partners opened 0 new positions and closed 0 in Q3 2019.
  • venBio Partners's portfolio value fell 6.5% quarter-over-quarter to $211M.

Based on venBio Partners's 13F filing for Q3 2019, filed 14 Nov 2019.